Abstract
Although the history of the development of 5- (3, 3-dimethyl-triazen-l-yl) imidazole-4-carboxamide (DTIC; NSC 45388) has been fully documented (1–5) a definitive account of the mode of action of the drug has yet to appear. There are almost as many theories purporting to explain the mode of action of DTIC as there are chemists and biochemists who, ensnared by the apparent deceptive simplicity of the molecule, have responded to the challenge but abjectly failed in the task of unravelling its perverse secrets.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Schepartz SA. (1976) Cancer Treatment Reports, 60, 123–124.
Montgomery JA. (1976) Cancer Treatment Reports,60, 125–134.
Venditti JM. (1976) Cancer Treatment Reports, 60, 135–140.
Bono VH. (1976) Cancer Treatment Reports, 60, 141–148.
Shealy YF. (1970) J. Pharm. Sci., 59, 1533–1558.
Stevens MFG (1976) Progr. Medicin. Chem., 13, 205–269.
Vaughan K, Stevens MFG. (1978) Chem. Soc. Rev., 7, 377–397.
Kreis W. (1977) Cancer, a Comprehensive Treatise. Ed. Becker FF. Plenum Press, Vol. 5, pp. 489–519.
Julliard M, Vernin G. (1981) Bull. Soc. chim. France II, 150–159.
Shealy YF, Krauth CA, Montgomery JA. (1962) J. Org. Chem.,27. 2150–2154.
Shealy YF, Struck RF, Holum LB, Montgomery JA. (1961) J. Org. Chem., 26, 2396–2401.
Horton JK, Stevens MFG. (1981) J.C.S. Perkin Trans. I, 1433–1436.
Saunders PP, Schultz GA. (1970) Biochem.Pharmacol., 19, 911–919.
Gerulath AH, Ti Li Loo, (1972) Biochem. Pharmacol., 21, 2335–2343.
Gerulath AH, Barranco SC, Humphrey RM. (1974) Cancer Res., 34, 1921–1925.
Saunders PP, Chao L-Y. (1974) Cancer Res., 34, 2464–2469.
Baird GM, Willoughby MLN. (1978) Lancet, 681.
Shealy YF, Krauth CA, Clayton SJ, Shortnacy AT, Laster WR. (1968) J. Pharm. Sci., 57, 1562–1568.
Horton JK, Stevens MFG. (1981) J. Pharm. Pharmacol., 33, 808–811.
Mizuno K, Tsujino M, Takada M, Hayashi M, Atsumi K, Asano K, Matsuda T. (1974) J. Antibiotics, 27, 775–782.
Mizuno K, Yaginuma S, Hayashi M, Takada M, Muto N, (1975) J. Ferment. Technol., 53, 609–619.
Ambroz HB, Golding BT, Kemp TJ. (1982) J.C.S. Chem. Commun., 414.
Kang UG, Schecter H. (1978) J. Amer. Chem. Soc., 100, 651–652.
Bru N, Vilarrasa J. (1980) Chemistry Letters, 1489–1492.
Rofstad EK, Brustad T, Johannessen JV, Mossige J. (1977) Br. J. Radial., 50, 314–320.
Rauth AM, Mohindra JK.(1981) Cancer Res., 41, 4900–4905.
Stevens MFG, Simmonds RJ, Langdon SP. Unpublished results.
Pool BL. (1979) J. Cancer Res. Clin. OncoZ., 93, 221–231.
Hansch C, Smith N, Engle R, Wood H. (1972) Cancer Chemother. Reports, 56, 443–456.
Hatheway GJ, Hansch C, Kim KH, Milstein SR, Schmidt CL, Smith RN, Quinn FR. (1978) J. Medicin. Chem., 21, 563–574.
Edwards SL, Sherfinski JS, Marsh RE. (1974) J. Amer. Chem. Soc., 96, 2593–2597.
Kolar GF, Preussmann R. (1971) Z. Naturforsch. B, 26, 950–953.
Dunn WJ, Greenberg MJ, Callejas SS. (1976) J. Medicin.Chem. 19, 1299–1301.
Giraldi T, Guarino AM, Nisi C, Sava G. (1980) Pharmacol. Res. Commun., 12, 1–11.
Sava G, Giraldi T, Lassiani L, Nisi C. (1979) Cancer Treatment Reports, 63, 93–98.
Connors TA, Goddard PM, Merai K, Ross WCJ, Wilman DEV. (1976) Biochem. Pharmacol., 25, 241–246.
Audette RCS, Connors TA, Mandel HG, Merai K, Ross WCJ. (1973) Biochem. Pharmacol., 22, 1855–1864.
Puccetti P, Giampietri A, Fioretti MC. (1978) Experientia, 15, 799–800.
Haffner F, Christoffersen T. (1980) Acta Pharmacol. EtToxicol., 47, 93–97.
Preussmann R, von Hodenberg A, Hengy H. (1969) Biochem. Pharmacol., 18, 1–13.
Mizuno NS, Decker RW, Zakis B. (1975) Biochem. Pharmacol., 24, 615–619.
Skibba JL, Ramirez G, Beal DD, Bryan GT. (1970) Biochem. Pharmacol., 19, 2043–2051.
Hickman JA. (1978) Biochimie, 60, 997–1002.
Hansch C, Hatheway CJ, Quinn FR, Greenberg N. (1978) J. Medicin. Chem., 21, 574–577.
Giraldi T, Nisi C, Sava G. (1975) Biochem. Pharmacol., 24, 1793–1797.
Pittillo RF, Schabel FM, Skipper HE. (1970) Cancer Chemother. Reports, 54, 137–142.
Gescher A, Hickman JA, Simmonds RJ, Stevens MFG, Vaughan K. (1981) Biochem. Pharmacol., 30, 89–93.
Farina P, Gescher A, Hickman JA, Horton JK, D’Incalci M, Ross D, Stevens MFG, Torti L. Biochem. PharmacoZ., in press.
Gescher A, Hickman JA, Simmonds RJ, Stevens MFG, Vaughan K. (1978) Tetrahedron Letters, 5041–5044.
Julliard M, Vernin G, Metzger J. (1980) Synthesis, 116–117.
Horton JK, Stevens MFG. Unpublished results.
H. Zollinger. (1961) Diazo and Azo Chemistry. Interscience New York, p.185.
Hickman JA, Simmonds RJ, Kolar GF, (1980) Brit. J. Cancer, 142, 170.
Hickman JA. Unpublished results.
Kolar GF, Carubelli R. (1979) Cancer Letters, 7, 209–214.
Kolar GF, Maurer M, Wildschütte. (1980) Cancer Letters, 10, 235–241.
Ti Li Loo, Luce JK, Jardine JH, Frei E. (1968) Cancer Res., 28, 2448–2453.
Stevens MFG, Gescher A, Turnbull CP. (1979) Biochem Pharmacol., 28, 769–776.
Schwalbe CH, Simmonds RJ. Unpublished work.
Akhtar MH, McDaniel RS, Feser M, Oehlschlager AC. (1968) Tetrahedron, 24, 3899–3906.
Hopfinger AJ, Potenzone R. (1982) Mol. PharmacoZ., 21, 187–195.
Gescher A, Hickman JA, Stevens MFG. (1979) Biochem. Pharmacol., 28, 3235–3238.
Lassiani L, Nisi C, Sigon F, Sava G, Giraldi T. (1980) J. Pharm. Sci., 69, 1098–1099.
Clarke DA, Phillips FS, Sternberg SS, Barclay RK, Stock CC. (1953) Proc. Soc. Exp. Biol. Med., 84, 203–207.
Horton JK, Farina P, Gescher A, Hickman JA, Stevens MFG. Br. J. Cancer, in press.
Weinkam RJ, Shiba DA. (1978) Life Sciences, 22, 937–946.
Ionescu D, Neagu V, Dobre V, Niculescu-Duvaz I. (1981) Neoplasma, 28, 19–26.
Noyanalpan N, Özden S, Özden T. (1977) Ankara Ecz. Fak. Mec., 7, 104–110.
Giraldi T, Nisi C, Connors TA, Goddard PM. (1977) J. Medicin. Chem., 20, 850–853.
Dunn WJ, Greenberg MJ. (1977) J. Pharm. Sci., 66, 1416–1419.
Giraldi T, Goddard PM, Nisi C, Sigon F. (1980) J. Pharm. Sci., 69, 97–98.
Cowan DH, Bergsagel DE. (1971) Cancer Chemother. Reports, 55, 175–181.
Tronchet JMJ, Rachidzadeh F. (1979) Hely. Chini. Acta, 62, 971–977.
Larm O, Larsson K, Wannong M. (1977) Acta Chem. Scand., B31, 475–478.
Baki Av, Vaughan K. Carbohydrate Res., in press.
Baker BR. (1967) Design of Active-Site-Directed Irreversible Enzyme Inhibitors. John Wiley and Sons, Inc., New York.
Sinnott ML, Smith PJ. (1976) J.C.S. Chem. Commun., 223–224.
Godin JRP, Llanos G, Vaughan K, Renton KW. (1981) Can. J. Physiol. Pharmacol., 59, 1239–1244.
Stevens MFG. Unpublished results.
Comis RL. (1976) Cancer Treatment Reports. 60, 165–176.
Lin AJ, Ti Li Loo. (1978) J. Medicin. Chem., 21, 268–272.
Wilman DEV, Goddard PM. (1980) J. Medicin. Chem., 23, 1052–1054.
Wilman DEV. Personal communication.
O’Connor JE, Janusonis GA, Corey ER. (1968) Chem. Commun., 445–446.
Kuyper J, Van Vliet PI, Vrieze K. (1975) J. OrganometaZlic Chem., 96, 289–299.
Pfeiffer E, Kuyper J, Vrieze K. (1976) J. Organometallic Chem., 105, 371–378.
Kuyper J, Van Vliet PI, Vrieze K. (1976) J. Organometallic Chem., 105, 379–387.
Van Vliet PI, Kuyper J, Vrieze K. (1976) J. Organometallic Chem., 122, 99–111.
Iwata H, Yamamoto I, Muraki K. (1969) Biochem. Pharmacol., 18, 955–956.
Iwata H, Yamamoto, Gohda E, Morita K, Nishino K. (1972) Biochem. Pharmacol., 21, 2141–2144.
Iwata H, Yamamoto I, Gohda E. (1973) Biochem. PharmacoZ., 22, 1845–1854.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Martinus Nijhoff Publishers, The Hague, Boston, London
About this chapter
Cite this chapter
Stevens, M.F.G. (1983). DTIC: A Springboard to New Antitumour Agents. In: Reinhoudt, D.N., Connors, T.A., Pinedo, H.M., van de Poll, K.W. (eds) Structure-Activity Relationships of Anti-Tumour Agents. Developments in Pharmacology, vol 3. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-6798-4_10
Download citation
DOI: https://doi.org/10.1007/978-94-009-6798-4_10
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-009-6800-4
Online ISBN: 978-94-009-6798-4
eBook Packages: Springer Book Archive